Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,368,849
  • Shares Outstanding, K 55,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,130 K
  • 60-Month Beta 2.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.79
  • Number of Estimates 3
  • High Estimate -0.67
  • Low Estimate -0.93
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -5.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.25 +16.24%
on 02/10/20
25.83 -4.37%
on 01/22/20
-0.73 (-2.87%)
since 01/21/20
3-Month
8.90 +177.53%
on 11/25/19
43.56 -43.30%
on 12/23/19
+15.22 (+160.55%)
since 11/21/19
52-Week
6.75 +265.93%
on 10/01/19
43.56 -43.30%
on 12/23/19
+11.68 (+89.71%)
since 02/21/19

Most Recent Stories

More News
Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the...

ITCI : 24.70 (+0.57%)
Pivotal Study of CAPLYTA(TM) (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication...

ITCI : 24.70 (+0.57%)
7.5% Return Seen to Date on SmarTrend Intra-Cellular T Call (ITCI)

SmarTrend identified a Downtrend for Intra-Cellular T (NASDAQ:ITCI) on January 8th, 2020 at $27.19. In approximately 1 month, Intra-Cellular T has returned 7.54% as of today's recent price of $25.14.

ITCI : 24.70 (+0.57%)
Intra-Cellular T is Among the Companies in the Pharmaceuticals Industry with the Best Relative Performance (ITCI , RVNC , PRGO , OCUL , DERM )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

ITCI : 24.70 (+0.57%)
PRGO : 59.86 (+0.42%)
RVNC : 27.81 (+0.83%)
What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?

Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.

AMAG : 9.50 (+0.85%)
IMMU : 18.06 (+0.17%)
ITCI : 24.70 (+0.57%)
VCEL : 19.22 (+0.97%)
Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that...

ITCI : 24.70 (+0.57%)
Intersect Ent In is Among the Companies in the Pharmaceuticals Industry with the Best Relative Performance (XENT , ITCI , RVNC , TBPH , CTLT )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

XENT : 26.76 (-2.94%)
ITCI : 24.70 (+0.57%)
RVNC : 27.81 (+0.83%)
20.7% Return Seen to Date on SmarTrend Intra-Cellular T Call (ITCI)

SmarTrend identified a Downtrend for Intra-Cellular T (NASDAQ:ITCI) on January 8th, 2020 at $27.19. In approximately 1 month, Intra-Cellular T has returned 20.74% as of today's recent price of $21.55....

ITCI : 24.70 (+0.57%)
Intra-Cellular T has the Best Relative Performance in the Pharmaceuticals Industry (ITCI , PCRX , ZGNX , NKTR , ZTS )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

ITCI : 24.70 (+0.57%)
PCRX : 48.49 (-3.06%)
ZGNX : 30.16 (-2.46%)
SmarTrend Watching for Potential Pullback in Shares of Intra-Cellular T After 5.11% Gain

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $21.50 to a high of $22.85. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high...

ITCI : 24.70 (+0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ITCI with:

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

2nd Resistance Point 25.78
1st Resistance Point 25.24
Last Price 24.70
1st Support Level 24.04
2nd Support Level 23.39

See More

52-Week High 43.56
Fibonacci 61.8% 29.50
Fibonacci 50% 25.16
Last Price 24.70
Fibonacci 38.2% 20.81
52-Week Low 6.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar